EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of Subtherapeutic Tylvalosin Against Mycoplasma hyopneumoniae : Implications For Respiratory Microbiome Dysbiosis and Swine Lung Health

Leonardo Teófilo Toledo iD, Richard Costa Polveiro iD, Caio Augustus Diamantino, Gustavo Manoel Rigueira Simão, Carlos Eduardo Real Pereira iD, Eduardo de Freitas Costa iD, Maria Aparecida Scatamburlo Moreira iD, Fernanda Simone Marks iD

Transboundary and Emerging Diseases · 2025

DOI: 10.1155/tbed/8903237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transboundary and Emerging Diseases, 2025. Verfasst von Leonardo Teófilo Toledo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medicine, Federal University of Viçosa, Viçosa 36570-900, Minas Gerais, Brazil. Hauptthemen laut MEDLINE: Mycoplasma hyopneumoniae, Tylosin, Pneumonia of Swine, Mycoplasmal, Microbiota. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de Minas Gerais.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enzootic pneumonia (EP) caused by Mycoplasma hyopneumoniae ( M. hyopneumoniae ) has a significant impact on swine production. Subtherapeutic exposures of tylvalosin in swine, often due to inconsistent dosing in feed or water, promote antimicrobial resistance. This study investigated the efficacy of 1.0625 mg/kg/day of tylvalosin administered for 7 days via feed to pigs experimentally infected with the UFV01 strain of M. hyopneumoniae and its impact on the respiratory microbiome. Thirty landrace x large white female piglets were divided into three groups: G1 (negative control, n = 2), G2 (infected, n = 14) and G3 (infected and treated, n = 14). Clinical signs, seroconversion, macroscopic and microscopic lung lesions and bacterial load were assessed. The respiratory microbiota of swine was analysed through 16S rRNA gene sequencing, followed by bioinformatics analyses. While G1 piglets remained healthy, G2 and G3 piglets developed lung lesions consistent with EP, although no significant difference was observed between these groups. Seroconversion was higher in G2 (90.9%) than in G3 (45.5%) at 35 days post‐infection, suggesting modulation of the humoral immune response by tylvalosin. Microbiota analyses revealed a significant shift in post‐infection composition, with infected pigs exhibiting reduced alpha diversity and distinct beta diversity compared to healthy pigs. M. hyopneumoniae dominated the respiratory microbiome of infected animals, drastically reducing the abundance of other taxa, notably Stenotrophomonas maltophilia . While tylvalosin treatment partially restored alpha diversity and shifted the microbiota composition towards the control group, it failed to eliminate M. hyopneumoniae . Variivorax , Ralstonia and Pseudomonas were identified as potential biomarkers for respiratory health and treatment response. These findings emphasise the complex relationship between M. hyopneumoniae infection, suboptimal tylvalosin dosage and resulting respiratory microbiome dysbiosis. Identifying and correcting the inappropriate use of antimicrobial dosages in clinical and preventive treatments, as well as promoting research focused on optimising dosage strategies and management practices, is essential for swine production and for reducing antimicrobial resistance. Moreover, maintaining a balanced microbiota may be a key factor in achieving healthier swine production, both in terms of animal welfare and food safety for consumers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycoplasma hyopneumoniaeTylosinPneumonia of Swine, MycoplasmalMicrobiotaAnti-Bacterial AgentsDysbiosisAnimalsSwineFemaleLungRNA, Ribosomal, 16S

Stichwörter der Autor:innen

UFV01antibioticsenzootic pneumoniaexperimental challengemicrobiotarespiratory disease

Substanzen

TylosinAnti-Bacterial AgentstylvalosinRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Department of Veterinary Medicine, Federal University of Viçosa, Viçosa 36570-900, Minas Gerais, Brazil.
  • Faculty of Veterinary Medicine and Animal Science, Federal University of Uberlândia, Uberlândia 38410-337, Minas Gerais, Brazil.
  • Agroceres PIC Company, Rio Claro 13502-741, São Paulo, Brazil.
  • Department of Epidemiology, Bioinformatics and Animal models, Wageningen Bioveterinary Research, Lelystad, Flevoland, Netherlands.

ORCID-Profile: Leonardo Teófilo Toledo, Richard Costa Polveiro, Carlos Eduardo Real Pereira, Eduardo de Freitas Costa, Maria Aparecida Scatamburlo Moreira, Fernanda Simone Marks

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais

Zitieren

APA

Toledo, L. T., Polveiro, R. C., Diamantino, C. A., Simão, G. M. R., Pereira, C. E. R., Costa, E. F., Moreira, M. A. S., & Marks, F. S. (2025). Use of Subtherapeutic Tylvalosin Against Mycoplasma hyopneumoniae : Implications For Respiratory Microbiome Dysbiosis and Swine Lung Health. Transboundary and Emerging Diseases. https://doi.org/10.1155/tbed/8903237

Vancouver

Toledo LT, Polveiro RC, Diamantino CA, Simão GMR, Pereira CER, Costa EF, et al. Use of Subtherapeutic Tylvalosin Against Mycoplasma hyopneumoniae : Implications For Respiratory Microbiome Dysbiosis and Swine Lung Health. Transboundary and Emerging Diseases. 2025. doi:10.1155/tbed/8903237

BibTeX
@article{Toledo2025,
  author = {Toledo, Leonardo Teófilo and Polveiro, Richard Costa and Diamantino, Caio Augustus and Simão, Gustavo Manoel Rigueira and Pereira, Carlos Eduardo Real and Costa, Eduardo de Freitas and Moreira, Maria Aparecida Scatamburlo and Marks, Fernanda Simone},
  title = {Use of Subtherapeutic Tylvalosin Against Mycoplasma hyopneumoniae : Implications For Respiratory Microbiome Dysbiosis and Swine Lung Health},
  journal = {Transboundary and Emerging Diseases},
  year = {2025},
  doi = {10.1155/tbed/8903237}
}
Kostenlos starten →